Lineage Cell Therapeutics (LCTX) Common Equity (2010 - 2026)
Lineage Cell Therapeutics' Common Equity was $60.92 million in Q2 2026, up 29.3% from $47.11 million a year earlier and up 15.6% from the prior quarter.
Lineage Cell Therapeutics (LCTX) Common Equity (2010 - 2026) Analysis & Trends
At the end of FY2025, Common Equity at Lineage Cell Therapeutics came in at $44.55 million, down 42.2% from FY2024.
- Common Equity shows a five-year compound annual growth rate of -14.1% (FY2020 to FY2025).
- In earlier years, Common Equity was $77.01 million in FY2024 (+24.2%), $62.02 million in FY2023 (-13.8%), $71.94 million in FY2022 (-20.9%) and $90.9 million in FY2021 (-4.4%).
- The Q2 2026 figure marks the highest quarterly Common Equity since Q1 2025.
- Compared with a year earlier, Common Equity was higher in three of the last eight quarters, with an average decline of 13.7%.
- The best year-over-year quarter for Common Equity over five years was Q3 2021 (growth of 32.6%); the worst was Q3 2025 (a decline of 66.0%).
- Per Business Quant data, LCTX's Common Equity in the three quarters before Q2 2026 was $52.7 million (Q1 2026), $44.55 million (Q4 2025) and $22.04 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Lineage Cell Therapeutics | 245.32 Mn | 43.73 Mn | - | 60.92 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 60.92 Mn |
| Mar 31, 2026 | 52.70 Mn |
| Dec 31, 2025 | 44.55 Mn |
| Sep 30, 2025 | 22.04 Mn |
| Jun 30, 2025 | 47.11 Mn |
| Mar 31, 2025 | 77.66 Mn |
| Dec 31, 2024 | 77.01 Mn |
| Sep 30, 2024 | 64.79 Mn |
| Jun 30, 2024 | 66.88 Mn |
| Mar 31, 2024 | 70.99 Mn |
| Dec 31, 2023 | 62.02 Mn |
| Sep 30, 2023 | 66.66 Mn |
| Jun 30, 2023 | 71.26 Mn |
| Mar 31, 2023 | 69.02 Mn |
| Dec 31, 2022 | 71.94 Mn |
| Sep 30, 2022 | 77.55 Mn |
| Jun 30, 2022 | 81.50 Mn |
| Mar 31, 2022 | 85.22 Mn |
| Dec 31, 2021 | 90.90 Mn |
| Sep 30, 2021 | 119.59 Mn |
Lineage Cell Therapeutics Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=LCTX&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "LCTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=LCTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();